Lisata Therapeutics Announces Completion of Enrollment in its Phase 2a BOLSTER Trial of Certepetide in First-Line Cholangiocarcinoma

Complete enrollment achieved nearly six months ahead of plan Addition of second-line cholangiocarcinoma arm to BOLSTER trial For more information on the BOLSTER trial, please visit https://clinicaltrials.gov/study/NCT05712356. Top-line data now anticipated mid-2025 BASKING RIDGE, N.J., July 16, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) ("Lisata" or the "Company"), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and ot ...